top stories

Plot thick­ens around Leg­end Biotech, Gen­Script with founder Frank Zhang's ar­rest

8 hours ago
People
China

Bris­tol My­ers fronts new Schrödinger al­liance with $55M up­front, ex­pand­ing pre­ci­sion on­col­o­gy pro­file

7 hours ago
Deals

Tech bil­lion­aire Pe­ter Thiel backs a lead­ing psy­che­del­ic drug de­vel­op­er

7 hours ago
Venture

Bob Nelsen rais­es $800M and re­cruits a star-stud­ded board to build the 'Fox­con­n' of biotech

5 hours ago
Startups

Latest

Most read

In fi­nal days at Mer­ck, Roger Perl­mut­ter bets big on a lit­tle-known Covid-19 treat­ment

10 hours ago
Deals
Coronavirus

Am­gen sev­ers 14-year Cy­to­ki­net­ics part­ner­ship, bail­ing on ome­cam­tiv af­ter mixed PhI­II re­sults

6 hours ago
R&D

News brief­ing: Ab­b­Vie part­ner Teneo­bio ex­pands tech li­cense with CAR-T play­er Po­sei­da; Ar­genx buys PRV from Bay­er for ...

6 hours ago
News Briefing

From a pair of Air Jor­dans to a $200M-plus IPO, Carl Hansen is craft­ing an overnight R&D for­tune fu­eled by Covid-19

9 hours ago
IPOs

Eiger nabs the first FDA ap­proval for Prog­e­ria, an ul­tra-rare pre­ma­ture ag­ing dis­ease, with an old Mer­ck drug

10 hours ago
Regulatory

Cata­ma­ran Bio sails in­to the CAR-NK wa­ters with a $42M launch round

10 hours ago
Venture
Cell/Gene Tx
see latest stream
People

UP­DAT­ED: Vivek Ra­maswamy’s Meta­vant hits a brick wall, aban­don­ing a lead pro­gram for di­a­betes. And there’s ...

3 days ago

For­mer MiMedx CEO and COO are con­vict­ed on fraud, con­spir­a­cy charges

3 days ago

Amid scruti­ny of ex­ec stock sales, SEC chair­man echoes calls for 'cool­ing-off pe­ri­od' in trad­ing plans

4 days ago
Startups

George Church backs a start­up so­lu­tion to the mas­sive gene ther­a­py man­u­fac­tur­ing bot­tle­neck

3 days ago

An Ox­ford spin­out rais­es $44M as it looks to res­ur­rect an old Roche an­ti­body in pur­suit of a rare dis­ease

4 days ago

MPM, DCVC Bio back $53M round for a bold con­cept: Let pa­tients make their own CAR-T in vi­vo

5 days ago
Deals

In an ap­par­ent R&D about-face, Eli Lil­ly part­ners with Pre­ci­sion Bio­Sciences on genome edit­ing in a deal worth up to ...

3 days ago

As­traZeneca, Sam­sung quit race to de­vel­op Rit­ux­an copy­cat as ri­vals crowd out the mar­ket

3 days ago

No­var­tis bags Mesoblast's stem cell ther­a­py for ARDS, in­clud­ing in Covid-19, in a deal worth up to $1.2B+

3 days ago
IPOs

Sean Bo­hen hauls in a mul­ti­mil­lion-dol­lar wind­fall as his new­ly adopt­ed biotech bags a $209M-plus IPO

4 days ago

4DMT shoots for a $75M IPO, its sec­ond at­tempt to go pub­lic with its gene ther­a­py vec­tor pro­grams

5 days ago

Sil­ver­back files to go pub­lic, po­ten­tial­ly adding to this year's record-high biotech IPO raise

Last week

Premium storiesSee all

TCR pi­o­neer Im­muno­core scores a first with a land­mark PhI­II snap­shot on over­all sur­vival for a rare melanoma

15 hours ago
R&D

Scoop: SR One crew com­pletes a com­pli­cat­ed spin­out from Glax­o­SmithK­line. And now they have a $500M fund to in­vest on ...

4 days ago
Venture

Rene­go­ti­ate the $6B CVR deal Bris­tol My­ers made for the Cel­gene buy­out? Caforio says that’s not hap­pen­ing

5 days ago
Deals

A phar­ma R&D chief jumps to a bud­ding new start­up fac­to­ry — and this time he’s found 'some­thing com­plete­ly ...

Last week
People
Startups

Don't missSee all

UP­DAT­ED: As­traZeneca, Ox­ford on the de­fen­sive as skep­tics dis­miss 70% av­er­age ef­fi­ca­cy for Covid-19 vac­cine

12 hours ago
Coronavirus

Jen­nifer Zi­olkows­ki re­signs from CFO post at Sol­id Bio­sciences; Sean Bo­hen's Ole­ma On­col­o­gy adds San­dra Horn­ing to ...

3 days ago
Peer Review

Pfiz­er and BioN­Tech are send­ing the first Covid-19 vac­cine to the FDA to­day

3 days ago
Coronavirus

Gilead touts piv­otal da­ta for new kind of HIV ther­a­py, open­ing to­wards large po­ten­tial mar­ket

5 days ago
R&D

Endpoints Standouts

The End­points 11: Here are some of the most promis­ing star­tups in biotech. And Covid-19 is­n't go­ing to stop them

Last month
Startups
In Focus

The 20 un­der 40: In­side the next gen­er­a­tion of bio­phar­ma lead­ers

7 months ago
People
Special

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

10 months ago
Special
Pharma

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

Last year
People
R&D

Peer review See all

Nov
13

Af­ter No­vo Nordisk's ac­qui­si­tion of Cor­vidia, Ram Ai­yar takes the helm at Ko­r­ro Bio; Sil­ver­back gets a new CFO to go ...

Nov
6

Karin Rosén moves on from GSK, now play­ing dual roles at Hori­zon; Gilead looks to Jared Baeten to take com­mand of ...

Oct
30

Trou­bled Unum re­brands as Co­gent Bio­sciences, re­places CEO Chuck Wil­son with An­drew Rob­bins; Jen­nifer Fox ap­point­ed ...

Oct
23

Arndt Rolfs steps aside as Cen­to­gene CEO, with An­drin Os­wald named as his suc­ces­sor; João Sif­fert lands an­oth­er CEO ...

Oct
16

Ameet Nath­wani re­bounds from Sanofi purge to helm Dew­point; Ali Mor­taza­vi named CEO at e-ther­a­peu­tics

R&D channel feed

4 days ago

Look­ing for leg up in he­mo­phil­ia B gene ther­a­py race, uniQure flash­es da­ta that helped lead to $2B CSL deal

In the two-head­ed race to de­vel­op the first gene ther­a­py for he­mo­phil­ia B, uniQure just got a ma­jor leg up.

READ MORE

Bris­tol My­ers Squibb Foun­da­tion launch­es pro­gram to tack­le di­ver­si­ty prob­lem in clin­i­cal tri­als

5 days ago
Pharma

GSK and Vi­iV score break­through ther­a­py des­ig­na­tion in HIV pre­ven­tion, as Tru­va­da show­down draws near­er

6 days ago
Regulatory
latest in R&D

BeiGene beefs up PD-1 da­ta with pos­i­tive PhI­II re­sults for tislelizum­ab, this time in metasta­t­ic NSCLC

6 days ago

The pri­ma­ry failed. The key sec­ondary failed. But this biotech still be­lieves it can win an FDA OK in ALS

6 days ago

Alk­er­mes is hand­ed a CRL for ‘3831, mark­ing an­oth­er set­back on the R&D front

6 days ago
Regulatory

Fa­heem Has­nain is go­ing back to run­ning a biotech start­up. And he has his work cut out for him

Last week
People

Mod­er­na says its vac­cine is 94.5% ef­fec­tive at pre­vent­ing Covid-19, ap­pears to stop se­vere dis­ease

Last week
Coronavirus
see latest stories

Pharma channel feed

3 days ago

With on­ly weeks left in his pres­i­den­cy, Trump makes a fi­nal, long-shot bid to re­make US drug pric­ing

As the cur­tain clos­es on his ad­min­is­tra­tion, Pres­i­dent Don­ald Trump is us­ing his fi­nal weeks in of­fice to push one of his longest-run­ning cam­paign promis­es of low­er­ing pre­scrip­tion ...

READ MORE

J&J joins Bris­tol My­ers Squibb with $100M com­mit­ment to di­ver­si­ty ef­forts

5 days ago

Phar­ma lob­by­ist and long­time Biden loy­al­ist Steve Ric­chet­ti joins the in­ner cir­cle head­ed to the White House as drug ...

5 days ago
People
latest in Pharma

An­a­lysts poured cold wa­ter, but FDA gives a fast-pass for Sanofi's new Pompe dis­ease drug

5 days ago
Regulatory

Retrophin no more: Shkre­li's lega­cy dis­ap­pears as for­mer com­pa­ny be­comes Tra­vere Ther­a­peu­tics

Last week
People

French health prod­ucts agency yanked in­to le­gal bat­tle over birth de­fects caused by Sanofi's De­pakine

Last week
Regulatory

Gov­ern­ment gears for un­prece­dent­ed chal­lenge of Eli Lil­ly an­ti­body roll­out as ef­fi­ca­cy ques­tions linger

Last week
Coronavirus

Bris­tol My­ers posts an­oth­er win for their Ote­zla com­peti­tor, this time with PhII da­ta in pso­ri­at­ic arthri­tis

2 weeks ago
R&D
see latest stories

Coronavirus channel feed

11 hours ago

Trail­ing Eli Lil­ly by 12 days, Re­gen­eron gets the FDA OK for their Covid-19 an­ti­body cock­tail

A month and a half af­ter be­com­ing the ex­per­i­men­tal treat­ment of choice for a new­ly di­ag­nosed pres­i­dent, Re­gen­eron's an­ti­body cock­tail has re­ceived emer­gency use au­tho­riza­tion from ...

READ MORE

It's of­fi­cial: Pfiz­er and BioN­Tech have sub­mit­ted their Covid-19 vac­cine to the FDA — and the agency cir­cled a date ...

3 days ago

Covid-19 roundup: WHO rec­om­mends against 'high cost' remde­sivir, dis­ap­point­ing Gilead; EU deals with Pfiz­er/BioN­Tech, ...

3 days ago
latest in Coronavirus

UP­DAT­ED: Eli Lil­ly picks up an­oth­er Covid-19 EUA as reg­u­la­tors wave through its Olu­mi­ant plus remde­sivir com­bo

3 days ago

CEO Ugur Sahin: BioN­Tech and Pfiz­er will file for a Covid-19 vac­cine EUA on Fri­day

4 days ago
Regulatory

A new study breathes life in­to an all-but-dead ap­proach to treat­ing se­vere Covid-19

4 days ago

Alex Azar, re­fus­ing to ac­knowl­edge elec­tion re­sults, says they're not work­ing with Biden team on vac­cine roll­out

4 days ago

Covid-19 roundup: J&J en­ters PhI­II with a two-dose reg­i­men to play safe; As­traZeneca, Ox­ford tout promis­ing da­ta in el­der­ly

4 days ago
see latest stories